靶向治疗：贝伐单抗——它是否已到达最终归宿？ - Suppr

Suppr

超能文献

Targeted therapies: bevacizumab--has it reached its final resting place?

作者信息

Kerr David J, Young Annie M

机构信息

Nuffield Department of Clinical and Laboratory Sciences, John Radcliffe Hospital, Headley Way, Oxford OX3 9DU, UK.

出版信息

Nat Rev Clin Oncol. 2011 Mar 8;8(4):195-6. doi: 10.1038/nrclinonc.2011.32.

DOI:10.1038/nrclinonc.2011.32

PMID:21386819

Abstract

摘要

相似文献

Targeted therapies: bevacizumab--has it reached its final resting place?

Nat Rev Clin Oncol. 2011 Mar 8;8(4):195-6. doi: 10.1038/nrclinonc.2011.32.

[Bevacizumab and radiotherapy].

Rev Mal Respir. 2008 Dec;25(10):1319-21. doi: 10.1016/s0761-8425(08)75095-2.

Bevacizumab: one treatment for all the seasons?

J Clin Oncol. 2008 Jan 20;26(3):511; author reply 511-2. doi: 10.1200/JCO.2007.15.0292.

Targeting angiogenesis in an age of personalized medicine.

Cancer Biol Ther. 2010 Nov 1;10(9):874-7. doi: 10.4161/cbt.10.9.14008.

Bevacizumab and surgery: what is the real risk?

Future Oncol. 2009 Sep;5(7):915-7. doi: 10.2217/fon.09.63.

Cancer: The nuances of therapy.

Nature. 2009 Mar 19;458(7236):290-2. doi: 10.1038/458290a.

Bevacizumab.

Nat Rev Drug Discov. 2005 May;Suppl:S8-9. doi: 10.1038/nrd1727.

Addition of bevacizumab to chemotherapy for treatment of solid tumors: similar results but different conclusions.

J Clin Oncol. 2011 Jan 20;29(3):254-6. doi: 10.1200/JCO.2010.32.0275. Epub 2010 Dec 13.

Circulating endothelial cells as biomarkers for patients receiving bevacizumab.

Lancet Oncol. 2011 Mar;12(3):217-8. doi: 10.1016/S1470-2045(11)70051-1.

Novel approaches to advanced breast cancer: bevacizumab and lapatinib.

J Natl Compr Canc Netw. 2007 Mar;5(3):314-23. doi: 10.6004/jnccn.2007.0026.

引用本文的文献

Editorial: Vascular co-option and beyond for cancer biology.

Front Oncol. 2023 Jun 19;13:1227540. doi: 10.3389/fonc.2023.1227540. eCollection 2023.

The measurement and modification of hypoxia in colorectal cancer: overlooked but not forgotten.

Gastroenterol Rep (Oxf). 2022 Aug 25;10:goac042. doi: 10.1093/gastro/goac042. eCollection 2022.

The notch ligand JAGGED1 as a target for anti-tumor therapy.

Front Oncol. 2014 Sep 25;4:254. doi: 10.3389/fonc.2014.00254. eCollection 2014.

Oncogenes and angiogenesis: a way to personalize anti-angiogenic therapy?

Cell Mol Life Sci. 2013 Nov;70(21):4131-40. doi: 10.1007/s00018-013-1331-3. Epub 2013 May 18.

Therapeutic antibodies against cancer.

Hematol Oncol Clin North Am. 2012 Jun;26(3):447-81, vii. doi: 10.1016/j.hoc.2012.02.013.

Gynecological cancer: First-line bevacizumab for ovarian cancer--new standard of care?

Nat Rev Clin Oncol. 2012 Feb 28;9(4):194-6. doi: 10.1038/nrclinonc.2012.28.

Reappraising antiangiogenic therapy for breast cancer.

Breast. 2011 Oct;20 Suppl 3(0 3):S56-60. doi: 10.1016/S0960-9776(11)70295-8.

本文引用的文献

Biomarkers to predict the clinical efficacy of bevacizumab in cancer.

Lancet Oncol. 2010 Dec;11(12):1172-83. doi: 10.1016/S1470-2045(10)70232-1.

Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08.

J Clin Oncol. 2011 Jan 1;29(1):11-6. doi: 10.1200/JCO.2010.30.0855. Epub 2010 Oct 12.

Direct evidence that bevacizumab, an anti-VEGF antibody, up-regulates SDF1alpha, CXCR4, CXCL6, and neuropilin 1 in tumors from patients with rectal cancer.

Cancer Res. 2009 Oct 15;69(20):7905-10. doi: 10.1158/0008-5472.CAN-09-2099. Epub 2009 Oct 13.

Reversible tumor growth acceleration following bevacizumab interruption in metastatic colorectal cancer patients scheduled for surgery.

Ann Oncol. 2008 Sep;19(9):1659-61. doi: 10.1093/annonc/mdn540. Epub 2008 Aug 5.

Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

J Clin Oncol. 2008 Apr 20;26(12):2013-9. doi: 10.1200/JCO.2007.14.9930.

Rapid vascular regrowth in tumors after reversal of VEGF inhibition.

J Clin Invest. 2006 Oct;116(10):2610-21. doi: 10.1172/JCI24612.

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

N Engl J Med. 2004 Jun 3;350(23):2335-42. doi: 10.1056/NEJMoa032691.

Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy.

Nat Med. 2001 Sep;7(9):987-9. doi: 10.1038/nm0901-987.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Targeted therapies: bevacizumab--has it reached its final resting place?

Nat Rev Clin Oncol. 2011 Mar 8;8(4):195-6. doi: 10.1038/nrclinonc.2011.32.

[Bevacizumab and radiotherapy].

Rev Mal Respir. 2008 Dec;25(10):1319-21. doi: 10.1016/s0761-8425(08)75095-2.

Bevacizumab: one treatment for all the seasons?

J Clin Oncol. 2008 Jan 20;26(3):511; author reply 511-2. doi: 10.1200/JCO.2007.15.0292.

Targeting angiogenesis in an age of personalized medicine.

Cancer Biol Ther. 2010 Nov 1;10(9):874-7. doi: 10.4161/cbt.10.9.14008.

Bevacizumab and surgery: what is the real risk?

Future Oncol. 2009 Sep;5(7):915-7. doi: 10.2217/fon.09.63.

Cancer: The nuances of therapy.

Nature. 2009 Mar 19;458(7236):290-2. doi: 10.1038/458290a.

Bevacizumab.

Nat Rev Drug Discov. 2005 May;Suppl:S8-9. doi: 10.1038/nrd1727.

Addition of bevacizumab to chemotherapy for treatment of solid tumors: similar results but different conclusions.

J Clin Oncol. 2011 Jan 20;29(3):254-6. doi: 10.1200/JCO.2010.32.0275. Epub 2010 Dec 13.

Circulating endothelial cells as biomarkers for patients receiving bevacizumab.

Lancet Oncol. 2011 Mar;12(3):217-8. doi: 10.1016/S1470-2045(11)70051-1.

Novel approaches to advanced breast cancer: bevacizumab and lapatinib.

J Natl Compr Canc Netw. 2007 Mar;5(3):314-23. doi: 10.6004/jnccn.2007.0026.

引用本文的文献

Editorial: Vascular co-option and beyond for cancer biology.

Front Oncol. 2023 Jun 19;13:1227540. doi: 10.3389/fonc.2023.1227540. eCollection 2023.

The measurement and modification of hypoxia in colorectal cancer: overlooked but not forgotten.

Gastroenterol Rep (Oxf). 2022 Aug 25;10:goac042. doi: 10.1093/gastro/goac042. eCollection 2022.

The notch ligand JAGGED1 as a target for anti-tumor therapy.

Front Oncol. 2014 Sep 25;4:254. doi: 10.3389/fonc.2014.00254. eCollection 2014.

Oncogenes and angiogenesis: a way to personalize anti-angiogenic therapy?

Cell Mol Life Sci. 2013 Nov;70(21):4131-40. doi: 10.1007/s00018-013-1331-3. Epub 2013 May 18.

Therapeutic antibodies against cancer.

Hematol Oncol Clin North Am. 2012 Jun;26(3):447-81, vii. doi: 10.1016/j.hoc.2012.02.013.

Gynecological cancer: First-line bevacizumab for ovarian cancer--new standard of care?

Nat Rev Clin Oncol. 2012 Feb 28;9(4):194-6. doi: 10.1038/nrclinonc.2012.28.

Reappraising antiangiogenic therapy for breast cancer.

Breast. 2011 Oct;20 Suppl 3(0 3):S56-60. doi: 10.1016/S0960-9776(11)70295-8.

本文引用的文献

Biomarkers to predict the clinical efficacy of bevacizumab in cancer.

Lancet Oncol. 2010 Dec;11(12):1172-83. doi: 10.1016/S1470-2045(10)70232-1.

Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08.

J Clin Oncol. 2011 Jan 1;29(1):11-6. doi: 10.1200/JCO.2010.30.0855. Epub 2010 Oct 12.

Direct evidence that bevacizumab, an anti-VEGF antibody, up-regulates SDF1alpha, CXCR4, CXCL6, and neuropilin 1 in tumors from patients with rectal cancer.

Cancer Res. 2009 Oct 15;69(20):7905-10. doi: 10.1158/0008-5472.CAN-09-2099. Epub 2009 Oct 13.

Reversible tumor growth acceleration following bevacizumab interruption in metastatic colorectal cancer patients scheduled for surgery.

Ann Oncol. 2008 Sep;19(9):1659-61. doi: 10.1093/annonc/mdn540. Epub 2008 Aug 5.

Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

J Clin Oncol. 2008 Apr 20;26(12):2013-9. doi: 10.1200/JCO.2007.14.9930.

Rapid vascular regrowth in tumors after reversal of VEGF inhibition.

J Clin Invest. 2006 Oct;116(10):2610-21. doi: 10.1172/JCI24612.

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

N Engl J Med. 2004 Jun 3;350(23):2335-42. doi: 10.1056/NEJMoa032691.

Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy.

Nat Med. 2001 Sep;7(9):987-9. doi: 10.1038/nm0901-987.